EU projects coordinated at KI

Denna sida på svenska

Projects within Horizon2020 Health, Demographic Change and Wellbeing

ENDpoiNTs – Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental Neurotoxicity

  • Project name: ENDpoiNTs
  • H2020-SC1-BHC-2018-2020 
  • Project period: 1 January 2019 – 31 December 2023
  • Funding: EUR 6.9 million
  • 16 partners
  • Coordinator:  Docent Joelle Rüeg, Institute of Environmental Medicine (IMM)

More reading at the IMM web portal (partly in Swedish)

BADGER – Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

  • Project name: BADGER
  • H2020-SMEINST-2-2016-2017
  • Project period: 1 December 2017 – 31 March 2020
  • Funding: EUR 3.6 million
  • 7 partners
  • Coordinator: Symcel Sverige AB
  • Principal Investigator: Christian G. Giske

More about this project on KI News

MultupleMS – Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine

  • Project name: MultipleMS
  • H2020-SC1-2016-RTD
  • Project period:  1 January 2017 –  31 December 2021
  • Project funding: EUR 14.7 million
  • 21 partners
  • Coordinator: Professor Ingrid Kockum

More on the project website

About this project in the database of the European Commission

BOOSTB4 – Stem cell therapy before birth against brittle bones disease

  • Project name: Boost Brittle Bones Before Birth 
  • H2020-PHC-2015-single-stage-RTD
  • Project period: 1 January 2016 – 31 December 2020
  • 12 partners
  • Coordinator: Dr Cecilia Götherström

More about BOOSTB4 on the project website

Read a news article about the upstart of this project

COSYN – Precision medicine in overlapping psychiatric disorders

  • Project name: Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders
  • H2020-PHC-2015-two-stage
  • Project period: 1 January 2016 – 31 December 2020
  • 14 partners
  • Coordinator: Professor Patrick Sullivan

COSYN is a precision medicine programme, with the goal to find an effective therapy for rare individuals with synaptic mutations causal to intellectual disability, autism, and/or schizophrenia. Novel patient-specific neuronal cell models will be developed to investigate the functionality of identified synaptic mutations, with the ultimate goal to be used for screening and identification of approved medications to be evaluated in individualized drug trials.

EDC-MixRisk – Secure chemicals for future generations

  • Project name: Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds 
  • H2020-PHC-2015-single-stage-RTD
  • Project period: 1 May –  30 April 2019
  • Funding: EUR 6.2 million 
  • 12 partners
  • Coordinator: Associate Professor Åke Bergman, Swetox

More about EDC-MixRisk on the project website

SMART2D – Type 2 diabetes prevention and management 

  • SMART2D 2016 logoProject name: Self management approach and reciprocal transfer for type 2 diabetes
  • Horizon 2020 Health – Research and innovation action (RIA)
  • Project period: 2 January 2015 – 31 March 2019 (51 months)
  • 6 partners
  • CoordinatorSenior lecturer Meena Daivadanam

The aim of SmART2D is to strengthen capacity for T2DM prevention and management through task-shifting among health care providers and community health workers, and expanding care networks through community-based peer support groups, by targeting three populations in different settings.

The objectives are to develop cross-lessons between the low-, middle- and high-income countries; to formulate facility and community strategies to improve access and adherence to prevention and management interventions for T2DM, and implement these strategies through a controlled study design; and to engage in policy dialogue throughout the process.

More on the SMART2D project website 

Collaborative projecs within the Marie Sklodowska-Curie Programme

SyDAD – Training programme focusing on synaptic dysfunktion in Alzheimer's Disease

  • Project name: Synaptic Dysfunction in Alzheimer Disease
  • H2020-MSCA-ETN-2015
  • Project period: 1 November 2015 – 31 October 2019
  • Project grant: EUR 3.8 million
  • 6 partners
  • Coordinator: Professor Bengt Winblad

More about SyDAD on the project website

Projects within FP7 theme Health

COUNTERSTROKE – Treatment against stroke

  • Project name: Treating stroke with Affibody molecules targeting the inflammatory mediator HMGB1
  • FP7 Health – Small or medium-scale focused research project
  • Project period: 1 October 2013 – 30 September 2018 (60 months)
  • Project funding: EUR 6 million
  • 6 partners
  • Coordinator: Professor Helena Erlandsson Harris

The COUNTERSTROKE consortium is going to develop molecules targeting the pro-inflammatory protein HMGB1 with the aim to bring a new treatment principle against stroke to clinical reality.

More on the COUNTERSTROKE project website

HUMAN – Healthy ageing

  • Project name: Health and understanding of metabolism, aging and nutrition
  • FP7 Health – Large-scale integrating project
  • Project period: 1 October 2013 – 30 August 2018 (60 months)
  • Project funding: EUR 12 million
  • 17 partners
  • Coordinator: Professor Paolo Parini 

The aim of HUMAN is to gain further insight into the interplay between genetics and physiology of metabolic diseases and longevity. The results gained might provide tools for individuals to better control their own health and ageing through diet and lifestyle.

The project attempts to tackle this fundamental issue by generating 'humanised' mouse models with livers and pancreatic beta cells originating from human donors using stem cell technology, making it possible to study the gene functions in human-derived organs. The human cells to be used originate either from patients affected by severe metabolic diseases or from individuals that enjoyed a complete lack of disease and exceptional longevity; 105 years or more.

More on the HUMAN project website

Projects within Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

RTCure - Prevent and treat Rheumatoid Arthritis through immune tolerising therapies

  • Project name: Rheuma Tolerance for Cure (RTCure)
  • Project period: 1 September 2017 – 31 August 2022
  • EU funding: 6 million Euro
  • 20 partners
  • Coordinator: Professor Lars Klareskog

More about the project on the EU website

Projects within EDCTP2

The EDCTP2 programme is funded by the EU Horizon 2020 through the European and Developing Countries Clinical Trials Partnership Association (EDCTP).

PROFORMA – development of systems for mass vaccination in East Afrika

  • name: Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa (PROFORMA)
  • EDCTP2, co-funded by the Swedish International Development Cooperation Agency, Karolinska Institutet, Pharmacy and Poisons Board (in Kenya), Muhimbili University of Helath and Allied Sciences (in Tanzania), and Tanzania Food and Drugs Authority.
  • Project period: 1 March 2018 – 28 February 2023 (60 months)
  • Funding: EUR 6 million
  • 10 partners
  • Coordinator: Senior researcher Eleni Aklillu, Department of Laboratory Medicine

More information at the project website

News article at KI News